The benefit of whole brain reirradiation in patients with multiple brain metastases by Zerrin Ozgen et al.
Ozgen et al. Radiation Oncology 2013, 8:186
http://www.ro-journal.com/content/8/1/186RESEARCH Open AccessThe benefit of whole brain reirradiation in
patients with multiple brain metastases
Zerrin Ozgen1*, Beste M Atasoy2, Aysegul Ucuncu Kefeli2, Askin Seker3, Faysal Dane4 and Ufuk Abacioglu5Abstract
Background: To assess the outcomes, symptom palliation and survival rates in patients who received repeat whole
brain radiotherapy (WBRT).
Methods: Twenty-eight patients who had progression of brain metastasis received a second course of WBRT.
Univariate log-rank testing and multivariate Cox regression analysis were used to determine the factors for death
among several variables (cumulative BED [BEDcumulative], primary tumor site, Karnofsky performance scale [KPS],
previous SRS, number of metastases and absence of extracranial metastases). Correlations between variables and
treatment response were evaluated with the Chi-squared test.
Results: The median KPS was 60 (range 50 to 100) at the initiation of reirradiation. The median time interval
between the two courses of WBRT was 9.5 months (range 3–27 months). The median doses of the first course and
the second course of WBRT were 30 Gy (range 20 to 30 Gy) and 25 Gy (range 20 to 30 Gy), respectively. The mean
BEDcumulative was 129.5 Gy (range 110 to 150 Gy). Severe or unexpected toxicity was not observed. Symptomatic
response was detected in 39% of the patients. The median overall survival following reirradiation was 3 months
(range 1 to 12 months, 95% CI 1.82-4.118). Survival was significantly better in responders (median 10 months,
95% CI 3.56-16.43) compared with non-responders (median 2 months, 95% CI 1.3-2.64) (p = 0.000). In multivariate
analysis, patients that had lung cancer (p = 0.01), initial KPS ≥60 (p = 0.03) or longer intervals to reirradiation
(p = 0.01) had significantly better survival rates.
Conclusions: A careful second course of whole brain irradiation might provide a symptomatic and survival benefit
in patients with good performance status and longer cranial progression-free intervals.
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Although the exact incidence of brain metastasis is un-
known, it is one of the most frequent manifestations in
the daily practice of oncology [1,2]. The prognosis of
these patients is usually poor. The median survival is
1 month in untreated patients and 4 to 6 months in
treated patients [3,4]. Whole brain radiotherapy (WBRT)
is the most common treatment modality and it prolongs
survival in these patients. It has an effect on palliation
and stabilizing cranial progression. In progressive situ-
ation, there are several options such as surgery and/
or stereotactic radiosurgery (SRS) for the treatment of* Correspondence: zerrinozgen34@hotmail.com
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reproduction in any medium, provided the orbrain metastasis. These therapeutic interventions can be
administered before and/or after WBRT. Moreover,
adding SRS or surgical resection to WBRT may reveal a
longer survival and a symptomatic control [5]. These
treatments may also have an additional benefit in the se-
lected patients such as younger age with good perform-
ance status, have less than four lesions and have no
evidence of systemic disease [6]. Nevertheless, in cases
of progression of the multiple metastases following any
of these modalities whole brain reirradiation can be re-
quired, but, the risk of toxicity limits this large volume-
based radiation therapy. Several factors i.e. the interval
between the first and second of WBRT, total cumulative
radiation dose and the fractionation scheme should be
considered to avoid an excessive toxicity [7].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of patients, diseases and
treatments in the study group
Characteristics
Age Median 52 years old (range 36
to 68 years)
Sex Male (11), Female (17)
Primary site of cancer Breast (6), Lung (22)
Histology of primary disease Invasive ductal cancer (breast);
Non-small cell lung cancer (lung)
KPS before the first course
of WBRT
Median 80 (range, 60–100)
KPS before the second course
of WBRT
Median 60 (range, 50–100)
First course RT (Gy) Median 30 Gy (range 20–30 Gy)
Second course RT (Gy) Median 25 Gy (range 20–30 Gy)
BEDcumulative Median 129.5 Gy (range 110–150 Gy)
Treatments Surgery before first WBRT (1)
SRS following first WBRT (5)
Surgery before and SRS after first
WBRT (5)
None (17)
WBRT whole brain radiotherapy, KPS Karnofsky performance scale,
RT radiotherapy, BED biological effective dose.
Figure 1 Overall survival following reirradiation in all patients.
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to assess whether there is both a benefit and an ad-
vantage for symptom palliations and survival in patients
who received repeat WBRT.
Methods
The current study has been approved by Ethics Commit-
tee in our faculty. A total of 28 patients were reirradiated
due to progression of brain metastasis anywhere in the
brain tissue, in the period between 2005 and 2013. Cha-
racteristics of the patients, diseases and treatments are
provided in Table 1. One (4%) patient underwent resec-
tion for intracranial disease before the first course of
WBRT. Five (18%) patients received SRS after the first
course of WBRT, and 5 (18%) patients both underwent
resection before and received SRS after the first course
of WBRT. All SRS was performed in the Gamma Knife
unit with a median of 14 Gy/single fraction (range 12 to
16 Gy). SRS was done median 11 months (range 4 to
14 months) following irradiation and second course of
WBRT was performed median 8 months (range, 4 to
25 months) following SRS. Meanwhile, 17 (61%) patients
did not receive any other treatment either before or after
the first course of WBRT. Twenty-four (86%) patients
had multiple metastases, and four (14%) patients had
3 to 4 metastases at the time of reirradiation. The
Figure 2 Overall survival according to responders (3 months) and non-responders (10 months) after reirradiation (p = 0.000).
Table 2 Analysis of variables for response to the second
course of WBRT
Responders (n) Non responders (n) p
Median dose
(BEDcumulative)
≥129.5 Gy 6 (43%) 8 (57%)
<129.5 Gy 5 (38%) 9 (62%) 0.50
Primary diagnosis
Lung 10 (45%) 12 (55%)
Breast 1 (16%) 5 (84%) 0.21
Initial KPS
<60 4 (50%) 4 (50%)
≥60 7 (54%) 13 (46%) 0.22
SRS
(−) 8 (64%) 10 (36%)
(+) 3 (30%) 7 (70%) 0.36
Number of metastasis
<5 2 (66%) 1 (33%)
≥5 9 (32%) 16 (68%) 0.33
BED biological effective dose, KPS Karnofsky performance scale,
SRS stereotactic radiosurgery.
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http://www.ro-journal.com/content/8/1/186biological effective dose (BED) was calculated using the
linear quadratic model: (BED = nd (1 + d / [a/b])) in grays,
where d = fraction dose (in grays), n = number of fractions,
nd =D = total physical dose (in grays), and a/b is the ratio
of 2 Gy [8]. The cumulative BED (BEDcumulative) was
calculated by the addition of the BED of the first and se-
cond courses of WBRT.
The median KPS was 60 (range 50 to 100) at the ini-
tiation of reirradiation. The most common neurological
symptoms were as follows: 57% headache, 32% nausea,
25% weakness, 25% ataxia and 4% visual changes. At the
time of the second course of WBRT, 16 (57%) patients
had systemic disease. All of the patients were adminis-
tered dexamethasone before and after reirradiation at a
median dose of 8 mg (range, 4 to 16 mg).
Survival time was defined as the time from the diagno-
sis of brain metastasis (OS1) and from the start of the
second course of WBRT (OS2) to the date of death. All
of the survival curves were plotted using the Kaplan-
Meier method. The median BEDcumulative dose, pri-
mary tumor site, median Karnofsky performance scale
(KPS), previous SRS, number of metastases and absence
of extracranial metastases were used as variables. A uni-
variate log-rank test and multivariate Cox regression ana-
lysis were used to determine the factors for death among
the variables. Treatment response related to variables was
evaluated using the Chi-squared test.
Table 3 Multivariate analysis for factors related to overall
survival following reirradiation
Factors (in favor of) p
Primary site (lung) 0.01
Pretreatment KPS (≥60) 0.03
Interval between two courses of WBRT (≥9.5 months) 0.01
SRS (application) 0.57
Extracranial metastasis (in control) 0.86
Number of metastasis in the brain (<5) 0.48
BEDcumulative (≥129.5 Gy) 0.62
KPS Karnofsky performance scale, WBRT whole brain radiotherapy,
SRS stereotactic radiosurgery, BED biological effective dose.
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The median dose of the first course of WBRT was 30 Gy
at 3 Gy per fraction (range 20 to 30 Gy). Different
fractionation schedules, such as 25 Gy (n = 21), 20 Gy
(n = 5) and 30 Gy (n = 2) in 10 fractions, were used. The
median time interval between the two courses of WBRT
was 9.5 months (range 3 to 27 months). The median
dose for the second course of WBRT was 25 Gy in 2 Gy
per fraction (n = 21) (range 20 to 30 Gy). Other frac-
tionation schedules were as follows: 20 Gy in 10 frac-
tions (n = 4); 20 Gy in 5 fractions (n = 1); and 30 Gy in
10 fractions (n = 2). Therefore, the mean BEDcumulative
was 129.5 Gy (range 110 to 150 Gy) (Table 1). Pa-
tients who received SRS had longer intervals than pa-
tients who did not (mean intervals, 14.9 ± 2.08 months vs.
10.15 ± 1.40 months, p = 0.47).
Severe or unexpected toxicity was not observed. Symp-
tomatic response was detected in 39% of patients, whereas
the remainder of the patients had stable or progres-
sive disease. The median OS1 was 12 months (range
5 to 28 months, 95% CI 10.13-13.86), and the OS2 was
3 months (range 1 to 12 months, 95% CI 1.82-4.118)Table 4 Results of reirradiation studies in summary
Sadikov [9] Hazuka [10] Cooper [11]
n = 72 n = 44 n = 52
WBRT
First course 20 Gy/5 fr 30 Gy/10 fr 30 Gy/10 fr
Second course 25 Gy/10 fr 25 Gy/8 fr 25 Gy/10 fr
Interval (median) 9.6 months 7.8 months >4 months (me
Other treatments to
the brain
Response (%) 40 27 42
Survival after reirradiation
(median)
4.1 months 2 months 4 months
WBRT whole brain radiotherapy, fr fraction, SRS stereotactic radiosurgery.(Figure 1). Following reirradiation, median survival
was significantly better in responders (10 months,
95% CI 3.56-16.43) than in non-responders (2 months,
95% CI 1.3-2.64) (p = 0.000) (Figure 2). This result
was independent of the presence of extracranial meta-
static disease.
In univariate analysis, none of the factors showed any
significance in terms of response to treatment (Table 2).
In multivariate analysis, patients that had lung cancer
(p = 0.01), had initial KPS ≥60 (p = 0.03) or had longer
intervals to reirradiation (p = 0.01) had significantly lon-
ger survival (Table 3).
Discussion
There are several options, such as surgery and/or SRS,
for patients that have a limited number of brain metasta-
ses in progression [5]. However, no consensus exists re-
garding the treatment for progressive multiple lesions in
the brain. These patients can require a second course of
whole brain irradiation, but the rationale for this treat-
ment has not been well described. Not only treatment of
symptomatic lesions but also the benefit of a survival ad-
vantage without any further toxicity are expected.
There have been more than a few articles in the lite-
rature describing whole brain reirradiation [9-14]. Some
of these studies have reported comparable fractionation
schemes and doses to those in our study [9-13] (Table 4).
Despite different response rates between 27% and 80%,
the median survival time in these studies was not longer
than 5 months. In our study, the median survival was
3 months, and the response rate was 39%, which were
very similar to the findings in the current literature.
Thus, repeat radiotherapy could be a useful option in
multiple intracranial progression. However, it is difficult
to draw any conclusions about anti-edema therapy be-
cause almost all of the patients in our study received
routine dexamethasone.Wong [12] Son [13] Our study
n = 86 n = 17 n = 28
30 Gy/10 fr 35 Gy/14 fr 30 Gy/10 fr
20 Gy/10 fr 21.6 Gy/12 fr 25 Gy/10 fr
an) 7.6 months 15 months 9.5 months
SRS in 9 patients SRS in 10 patients
Surgery in 4 patients
70 80 39
4 months 5.2 months 3 months
10 months (responders)
3 months (nonresponders)
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http://www.ro-journal.com/content/8/1/186The weak point of our study was that the side effects
could not be reported in grades or in greater detail due
to the retrospective nature of this study. Based on the
follow-up notes and data, we can say that none of our
patients suffered from severe neurotoxicity or died due
to reirradiation. Because of the importance of toxicity,
longer follow-up periods after the first course of WBRT
should be expected by clinicians. SRS between two
whole brain treatments might provide for longer in-
tervals, as in our study. However, it did not demonstrate
an advantage for survival in our study. In addition,
we had four patients whose intervals were shorter than
6 months. These four patients died at 1, 2, 4 and
7 months after therapy due to disease progression. Al-
though, whole brain parenchyma should only be irra-
diated in selected patients, because we believe that the
dose per fraction may be kept at ≤2 Gy to avoid toxicity.
We could not find any positive correlation between
dose increment and response in our patients in whom
the cumulative BED was almost 130 Gy. Hence, we ar-
gued that increasing the dose might not help to improve
the response or outcome, and 25 Gy in 10 fractions can
therefore be recommended for whole brain reirradiation.Conclusions
Patients who have good performance status, have cranial
progression-free intervals and who do not have prog-
ression of systemic disease might benefit from a second
course of whole brain radiotherapy. Further reports on
quality of life and toxicity analyses following reirradia-
tion could help to determine the state of this treatment.
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